Journey Medical Corporation Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

LICENSES (Details)

LICENSES (Details) $ in Thousands, ¥ in Billions						1 Months Ended				12 Months Ended
LICENSES (Details) $ in Thousands, ¥ in Billions	Jan. 02, 2025 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2023 JPY (¥)	Sep. 29, 2021 USD ($)	Jun. 29, 2021 USD ($) D	Dec. 31, 2024 USD ($)	Jan. 31, 2024 USD ($)	Mar. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)	Dec. 31, 2024 USD ($) item	Dec. 31, 2023 USD ($)	Nov. 11, 2024 USD ($)	Nov. 01, 2024 USD ($)
Assets and Licenses Acquired
Notice period for cancellation		30 days	30 days
Other revenue										$ 1,000	$ 19,519
Emrosi Agreement
Assets and Licenses Acquired
Total Upfront payment					$ 10,000
Upfront payment upon execution					$ 2,000
Remaining upfront payment				$ 8,000
Threshold Number Of Days For Upfront Payment \| D					90
Number of developmental milestone \| item										2
Milestone payments						$ 15,000	$ 3,000
Transformation of ownership and all assets of milestone payments					$ 15,000
Threshold additional contingent regulatory and commercial milestone payments payable					$ 150,000
Percentage of reduction in royalty upon launching of competitor products					50.00%
Amount received from FDA under the license, collaboration, and assignment agreement													$ 15,000
Emrosi Agreement \| Minimum
Assets and Licenses Acquired
Percentage of royalties payable on net sales					10.00%
Emrosi Agreement \| Maximum
Assets and Licenses Acquired
Percentage of royalties payable on net sales					14.00%
Asset purchase agreement \| Qbrexza
Assets and Licenses Acquired
Age of patients								9 years
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Period of royalty payments								2 years
Asset purchase agreement \| Royalty payment percentage for eight years thereafter \| Qbrexza
Assets and Licenses Acquired
Term of royalty								8 years
Asset purchase agreement \| Minimum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments								30.00%
Asset purchase agreement \| Minimum \| Royalty payment percentage for eight years thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments								12.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments								40.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for eight years thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments								19.00%
Asset purchase agreement \| Eli Lilly and Company \| Qbrexza
Assets and Licenses Acquired
Upfront fees								$ 12,500
Milestone payments payable								$ 144,000
License and supply agreement With DRL \| Accutane
Assets and Licenses Acquired
Amount of expense paid under the agreement									$ 5,000
Contingent amount payable									$ 17,000
Term of accutane									10 years
Termination accutane agreement period									180 days
New License Agreement
Assets and Licenses Acquired
Amount of obligation payment terminated		$ 10,000
Remaining obligation payments		45,000
Proceeds from non-refundable payment		$ 19,000
Other revenue											$ 19,000
New License Agreement \| Net sales of at least ¥4 billion (yen)
Assets and Licenses Acquired
Net sales \| ¥			¥ 4
Cutia License Agreement
Assets and Licenses Acquired
Other revenue										$ 1,000
Cutia License Agreement \| Amzeeq
Assets and Licenses Acquired
Milestone payment												$ 1,000
Other revenue										$ 1,000
Cutia License Agreement \| Subsequent Event \| Amzeeq
Assets and Licenses Acquired
Milestone payment received, net	$ 1,000